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Abstract a-Dystroglycan, a 156 kDa dystrophin-associated glycoprotein, binds laminin in skeletal muscle. Here we demonstrate that a-dystroglycan 
is a binding protein of laminin (AIBlIB2) and merosin (MIBlIB2) in peripheral nerve. Immunocytochemical nalysis demonstrates the localization 
of a-dystroglycan and merosin surrounding myelin sheath of peripheral nerve fibers. Biochemical analysis demonstrates that the 120 kDa peripheral 
nerve a-dystroglycan binds merosin as well as laminin. The binding of laminin and merosin is Ca*’ dependent and is inhibited by NaCl and heparin. 
Recently, merosin was shown to be deficient in the peripheral nerve of dy mice which have defects in myelination. The interaction between 
a-dystroglycan and merosin may play a role in the regulation of Schwann cell myelination and/or maintenance of myelin sheath. 
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1. Introduction 
a-Dystroglycan, a 156 kDa dystrophin-associated glycopro- 
tein, is presumed to be a proteoglycan bound to the external 
surface of striated muscle cell membrane [l-9]. Striated muscle 
a-dystroglycan binds the basement membrane component lam- 
inin, thus linking the sarcolemma nd the basement membrane 
[6,8,9]. a-Dystroglycan also binds the basement membrane 
component agrin which mediates the clustering of acetylcholine 
receptor in the neuromuscular junction, suggesting that 
a-dystroglycan may bind multiple forms of G domain-containing 
basement membrane molecules [lO-121. a-Dystroglycan is ex- 
pressed in non-muscle tissues such as brain, lung and kidney 
[6-81. In peripheral nerve, a-dystroglycan is expressed sur- 
rounding nerve fibers [13]. Thus far biological functions of 
a-dystroglycan in peripheral nerve remain obscure. 
The prototypical laminin molecule is a heterotrimer made up 
of three chains of classes A, Bl and B2 [14]. Each class of 
laminin chain has multiple isoforms and laminin exists in nu- 
merous trimeric isoforms in different tissues [ 141. In peripheral 
nerve, merosin, a laminin heterotrimer comprised of the M (an 
isoform of the A chain), B 1 and B2 chains [15-l 71, is expressed 
in the endoneurium surrounding Schwann cell and myelin 
sheath [ 15,18-201. So far biological functions and the putative 
receptor of merosin remain elusive in peripheral nerve. These 
findings, all together, raise a possibility that a-dystroglycan 
may be a hitherto-unidentified merosin receptor in peripheral 
nerve. To begin to address this intriguing possibility, we inves- 
tigated the status of expression and laminin-binding activities 
of a-dystroglycan in peripheral nerve. 
2. Materials and methods 
2.1. Immunocytochemical analysis using confocal laser scanning 
microscopy (cLSM) 
Immunostaining of cryosections (7pm) from rabbit peripheral nerve 
or teased peripheral nerve fibers [21] was performed as previously 
*Corresponding author. Fax: (81) (3) 3964 6397. 
described [I 3,221. Specimens were observed and fluorescent images 
were obtained on a Zeiss cLSM model LSM 310, employing an argon 
ion laser (2 = 488 nm). 
2.2. Affinity chromatography 
Crude membranes from bovine peripheral nerve were extracted at a 
protein concentration f 2 mgIml in a buffer containing 1% digitonin 
as previously described [2,4,22,23]. 1.2 ml of the extracts were incubated 
at 4°C overnight with 0.3 ml of Sepharose or wheat germ agglutinin 
(WGA)-Sepharose (Pharmacia). The Sepharose matrices were sepa- 
rated from the voids by centrifugation, washed extensively and eluted 
with SDS-sample buffer. Mouse EHS sarcoma laminin (Biomedical 
Technologies) and human placenta merosin (Chemicon) were coupled 
to CNBr-activated Sepharose 4B (Pharmacia). Peripheral nerve mem- 
branes were extracted at a protein concentration f 2 mg/ml in 50 mM 
Tris-HCl, pH 7.4, containing 1% digitonin, 0.5 M sucrose and 0.44 M 
NaCl [8]. The extracts were diluted IO-fold with 50 mM Tris-HCI, pH 
7.4, 1.11 mM CaCI, and 1.11 mM MgCl, to reduce the digitonin, 
sucrose and NaCl concentrations to O.l%, 50 mM and 44 mM, respec- 
tively. 10 ml of the diluted extracts were incubated at 4 “C overnight 
with 0.1 ml of laminin- or merosin-Sepharose. The Sepharose matrices 
were separated from the voids by centrifugation, washed extensively 
and eluted with a buffer containing 10 mM EDTA. The results were 
analyzed by 3312% SDS-PAGE, immunoblotting and blot overlay. 
2.3. Others 
Affinity-purified sheep antibody against cc-dystroglycan fusion pro- 
tein D and monoclonal antibody IIH6 against a-dystroglycan were 
characterized previously [68]. Monoclonal antibodies 2G9 against 
human M, 1 ID5 against human A, 4ElO against human Bl and 2E8 
against human B2 chains were purchased from Gibco. Nitrocellulose 
transfer overlays with laminin or merosin were performed as previously 
described [8], except hat the bound laminin and merosin were detected 
using affinity-purified rabbit antibody against mouse EHS laminin 
(Sigma). 
3. Results and discussion 
cLSM fluorescent images of a-dystroglycan and laminin in 
rabbit peripheral nerve are shown in Fig. 1. a-Dystroglycan, the 
M and Bl chains of laminin were localized surrounding myelin 
sheath of nerve fibers (Fig. la). Anti-B2 chain antibody 2E8 did 
not react with rabbit tissues but stained a similar region in 
human peripheral nerve (not shown). The A chain was not 
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Fig. 1. (a) cLSM analysis of a-dystroglycan and merosin in peripheral nerve. cLSM fluorescent and the corresponding phase-contrast images are 
shown. DG, M, A and Bl indicate a-dystroglycan, the M, A and Bl chains, respectively. Bar = lOpurn. (b) cLSM analysis of cc-dystroglycan i  teased 
peripheral nerve fibers. Shown are the thin-slice (0.4 pm) image obtained by optical knife and the axial, oblique and longitudinal views of the 
reconstructed three-dimensional images. Bar = 10 pm. 
detected in this site (Fig. la). Furthermore, double-im- 
munostaining analysis demonstrated the co-localization of 
a-dystroglycan and the M/B1 chains surrounding myelin sheath 
(not shown). In order to further clarify the site of expression 
of a-dystroglycan in peripheral nerve, we performed the im- 
munocytochemical analysis of teased peripheral nerve fibers 
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using cLSM. Immunoreactivity for a-dystroglycan was de- 
tected homogeneously on the surface of myelin sheath of teased 
peripheral nerve fibers and was not detectable in the node of 
Ranvier (Fig. lb), suggesting the localization of a-dystroglycan 
in the outer membrane of myelin sheath. 
Immunoblot analysis demonstrated that a-dystroglycan was 
enriched in peripheral nerve membranes (not shown) and was 
extracted by 1% digitonin (Fig. 2). As reported previously [ 131, 
peripheral nerve a-dystroglycan had a molecular mass of 120 
kDa (Fig. 2). The 120 kDa a-dystroglycan was quantitatively 
absorbed by WGA-Sepharose (Fig. 2), indicating that it is a 
membrane-associated glycoprotein with N-acetylneuraminic 
acid/N-acetylglucosamine r sidues. 
Laminin- and merosin-Sepharose absorbed, in the presence 
of 1 mM CaCl, and 1 mM MgCI,, the 120 kDa -dystroglycan 
from the digitonin extracts of peripheral nerve membranes, and 
the absorbed a-dystroglycan was eluted by 10 mM EDTA (Fig. 
3). When overlaid with laminin or merosin on the nitrocellulose 
transfers, the eluted a-dystroglycan bound both these proteins 
(Fig. 3). In order to confirm laminin and merosin binding of 
peripheral nerve a-dystroglycan, the nitrocellulose transfers of 
the digitonin extracts of peripheral nerve membranes were 
overlaid with laminin or merosin. The 120 kDa a-dystroglycan 
bound laminin and merosin in the presence of 1 mM CaCl, and 
1 mM MgCl, (Figs. 2 and 4). The binding of merosin was 
inhibited by the inclusion of 10 mM EDTA or EGTA in the 
overlay medium (Fig. 4). Addition of 20 mM CaCl,, but not 20 
mM MgCl,, in the overlay medium containing 10 mM EDTA 
restored merosin binding (Fig. 4). The absence of CaCl,, but 
not MgCl,, in the overlay medium also inhibited merosin bind- 
ing (not shown). These results demonstrate the Ca”-depend- 
ency of merosin binding. The binding of merosin was inhibited 
by the presence of 0.5 M NaCl or l,OOO-fold excess (w/w) of 
heparin in the overlay medium (Fig. 4). The binding properties 
of laminin to peripheral nerve a-dystroglycan were identical to 
those of merosin (not shown). 
Here we demonstrated the localization of a-dystroglycan and 
merosin surrounding myelin sheath of peripheral nerve fibers. 
Furthermore, immunocytochemical analysis of teased periph- 
eral nerve fibers suggests the localization of a-dystroglycan in 
the outer membrane of myelin sheath. We also demonstrated 
that the 120 kDa peripheral nerve a-dystroglycan bound mer- 
osin as well as laminin. All together, our results indicate that 
a-dystroglycan is a novel merosin-binding protein in peripheral 
nerve, most likely in the myelin sheath membrane. The size of 
a-dystroglycan varies among different tissues [6,8]. The molec- 
ular mass of peripheral nerve a-dystroglycan is comparable to 
that of the brain form (120 kDa), and is smaller by about 40 
kDa than that of the striated muscle or lung form (156 kDa) 
[6,8,13,24]. This is presumed to be due to differences in the 
post-translational modification, such as glycosylation, of 
a-dystroglycan [c&13]. However, the binding activities of lam- 
inin and merosin to peripheral nerve a-dystroglycan were sim- 
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Fig. 3. Laminin and merosin affinity column chromatography of pe- 
ripheral nerve membranes. After incubation of the digitonin extracts 
of peripheral nerve membranes with laminin- or merosin-Sepharose 
(Lam-Seph and Mer-Seph, respectively), proteins absorbed by the ma- 
trices were eluted with 10 mM EDTA and analyzed by SDS-PAGE. 
Shown are the gel stained with Coomassie blue (CB), the nitrocellulose 
transfer immunostained with monoclonal antibody IIH6 against 
a-dystroglycan (IIH6), and the nitrocellulose transfers overlaid with 
laminin (+Laminin) or merosin (+Merosin). A small amount of laminin 
(L) and merosin (M) were detached from the Sepharose matrices by 10 
mM EDTA. The 120 kDa peripheral nerve a-dystroglycan was not 
stained with Coomassie blue as in the skeletal muscle form [2,4]. Lam- 
inin- Sepharose was apparently more efficient han merosin-Sepharose 
in absorbing a-dystroglycan. This could be due to martial degradation 
of commercial merosin preparation as previously described [1], or the 
affinity of mouse EHS laminin to bovine peripheral nerve a-dystrogly- 
can might be higher than that of human placenta merosin. Molecular 
weight standards (Da x lo-‘) are shown on the left. 
ilar to the laminin-binding activities of skeletal muscle a-dystro- 
glycan [8]. 
Recently, the specific reduction of merosin M chain was 
demonstrated in skeletal muscle of patients with Fukuyama- 
type congenital muscular dystrophy (FCMD), a disease charac- 
terized by brain anomaly and muscular dystrophy [25]. The 
abnormality in the expression of a-dystroglycan in the sar- 
colemma of FCMD patients implicates the disturbance of the 
interaction between a-dystroglycan and merosin in the molecu- 
lar pathogenesis of FCMD [26]. The M chain is also deficient 
in skeletal muscle and peripheral nerve of & mice [27-291, 
which have muscular dystrophy and peripheral nerve dysmyeli- 
nation [27-311. Intriguingly, laminin is known to promote 
Schwann cell myelination [32,33]. Furthermore, the expression 
t 
Fig. 2. WGA column chromatography of peripheral nerve membranes. After incubation of the digitonin extracts of peripheral nerve membranes with 
Sepharose or WGA-Sepharose, proteins remaining in the voids (Voids) or absorbed by the matrices (Beads) were analyzed by SDS-PAGE. Shown 
are the gel stained with Coomassie blue (CB), the nitrocellulose transfer immunostained with monoclonal antibody IIH6 against a-dystroglycan 
(IIH6), and the nitrocellulose transfers incubated with the overlay medium containing laminin (+Laminin) or lacking laminin (-Laminin). The bands 
indicated by L are the endogenous peripheral nerve laminin. The 120 kDa peripheral nerve a-dystroglycan was not stained with Coomassie blue as 
in the skeletal muscle form [2,4]. Molecular weight standards (Da x lo-‘) are shown on the left. 
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Fig. 4. Merosin-binding properties of peripheral nerve or-dystroglycan. Nitrocellulose transfers of the digitonin extracts of peripheral nerve membranes 
were incubated, in the presence of 1 mM CaCI, and 1 mM MgC&, with the overlay medium containing merosin (+Merosin) or lacking merosin 
(-Merosin). The bands indicated by L are the endogenous peripheral nerve laminin. The binding of merosin to the 120 kDa peripheral nerve 
a-dystroglycan was inhibited by the inclusion of 10 mM EDTA (+EDTA) or EGTA (+EGTA) in the overlay medium. Addition of 20 mM CaC1, 
(+EDTA & Ca), but not 20 mM MgCI, (+EDTA & Mg), in the overlay medium containing 10 mM EDTA restored merosin binding. The binding 
of merosin was significantly reduced by the presence of0.5 M NaCl (+NaCl) or l,OOO-fold excess (w/w) of heparin (+Heparin) in the overlay medium. 
Molecular weight standards (Da x IO-‘) are shown on the left. 
of merosin is up-regulated during development of peripheral 
nerve [ 151, and merosin is expressed in differentiated Schwann 
cell neoplasms but not detectable in undifferentiated malignant 
schwannomas [34]. These findings indicate that the xpression 
of laminin/merosin in the basement membrane is associated 
with Schwann cell differentiation and myelination. Taken to- 
gether, our results raise an intriguing possibility that a-dystro- 
glycan may be involved in the regulation of Schwann cell mye- 
lination and/or maintenance of myelin sheath. The disturbance 
of the interaction between a-dystroglycan and merosin may 
play a role in the pathogenesis of peripheral neuropathy in dv 
mice. 
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